两种灭活SARS-CoV-2疫苗对有症状COVID-19感染疗效的随机临床试验
该研究为在阿联酋和巴林进行的随机双盲3期试验预设中期分析,纳入18岁以上无COVID-19病史的成人,随机接种WIV04(5 µg/剂)、HB02(4 µg/剂)灭活疫苗或铝佐剂对照,共2剂间隔21天。结果显示,相较于对照组,WIV04疫苗对有症状COVID-19的效力为72.8%(95%CI 58.1%-82.4%),HB02为78.1%(95%CI 64.8%-86.3%),严重不良事件罕见。
要点
- WIV04疫苗对有症状COVID-19效力72.8%,HB02效力78.1%。
- 接种组未发生重症COVID-19,对照组发生2例。
- 严重不良事件三组发生率相似且罕见。
核心结论
- 两种灭活SARS-CoV-2疫苗均显著降低成人有症状COVID-19风险,且严重不良事件罕见。
研究设计与样本
- 在阿联酋和巴林进行的随机、双盲、3期试验的预设中期分析。
主要发现
- 中位随访77天(范围1-121天)内,WIV04组有症状COVID-19发病率为12.1/1000人年(95%CI 8.3-17.8),HB02组为9.8/1000人年(95%CI 6.4-15.0),对照组为44.7/1000人年(95%CI 36.6-54.6)。
- 对照组发生2例重症COVID-19,疫苗组无重症病例。
- 每剂注射后7天内不良事件发生率在三组中为41.7%至46.5%;严重不良事件发生率WIV04组0.5%(64例)、HB02组0.4%(59例)、对照组0.6%(78例)。
临床怎么用
- 在成人中接种WIV04或HB02灭活疫苗可显著降低有症状COVID-19风险,且严重不良事件罕见,支持使用这些疫苗。
局限性
- 本文为预设中期分析,最终分析的数据收集尚未完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although effective vaccines against COVID-19 have been developed, additional vaccines are still needed. OBJECTIVE: To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines. DESIGN, SETTING, AND PARTICIPANTS: Prespecified interim analysis of an ongoing randomized, double-blind, phase 3 trial in the United Arab Emirates and Bahrain among adults 18 years and older without known history of COVID-19. Study enrollment began on July 16, 2020. Data sets used for the interim analysis of efficacy and adverse events were locked on December 20, 2020, and December 31, 2020, respectively. INTERVENTIONS: Participants were randomized to receive 1 of 2 inactivated vaccines developed from SARS-CoV-2 WIV04 (5 µg/dose; n = 13 459) and HB02 (4 µg/dose; n = 13 465) strains or an aluminum hydroxide (alum)-only control (n = 13 458); they received 2 intramuscular injections 21 days apart. MAIN OUTCOMES AND MEASURES: The primary outcome was efficacy against laboratory-confirmed symptomatic COVID-19 14 days following a second vaccine dose among participants who had no virologic evidence of SARS-CoV-2 infection at randomization. The secondary outcome was efficacy against severe COVID-19. Incidence of adverse events and reactions was collected among participants who received at least 1 dose. RESULTS: Among 40 382 participants randomized to receive at least 1 dose of the 2 vaccines or alum-only control (mean age, 36.1 years; 32 261 [84.4%] men), 38 206 (94.6%) who received 2 doses, contributed at least 1 follow-up measure after day 14 following the second dose, and had negative reverse transcriptase-polymerase chain reaction test results at enrollment were included in the primary efficacy analysis. During a median (range) follow-up duration of 77 (1-121) days, symptomatic COVID-19 was identified in 26 participants in the WIV04 group (12.1 [95% CI, 8.3-17.8] per 1000 person-years), 21 in the HB02 group (9.8 [95% CI, 6.4-15.0] per 1000 person-years), and 95 in the alum-only group (44.7 [95% CI, 36.6-54.6] per 1000 person-years), resulting in a vaccine efficacy, compared with alum-only, of 72.8% (95% CI, 58.1%-82.4%) for WIV04 and 78.1% (95% CI, 64.8%-86.3%) for HB02 (P < .001 for both). Two severe cases of COVID-19 occurred in the alum-only group and none occurred in the vaccine groups. Adverse reactions 7 days after each injection occurred in 41.7% to 46.5% of participants in the 3 groups; serious adverse events were rare and similar in the 3 groups (WIV04: 64 [0.5%]; HB02: 59 [0.4%]; alum-only: 78 [0.6%]). CONCLUSIONS AND RELEVANCE: In this prespecified interim analysis of a randomized clinical trial, treatment of adults with either of 2 inactivated SARS-CoV-2 vaccines significantly reduced the risk of symptomatic COVID-19, and serious adverse events were rare. Data collection for final analysis is pending. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04510207; Chinese Clinical Trial Registry: ChiCTR2000034780.
引用
- Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021. PMID: 34037666. doi:10.1001/jama.2021.8565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。